These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23676092)

  • 21. Sorafenib-induced pancreatitis.
    Amar S; Wu KJ; Tan WW
    Mayo Clin Proc; 2007 Apr; 82(4):521. PubMed ID: 17418082
    [No Abstract]   [Full Text] [Related]  

  • 22. Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy.
    Hioki T; Takama H; Makita S; Chen KR; Watanabe D; Akiyama M
    Eur J Dermatol; 2017 Oct; 27(5):546-547. PubMed ID: 29084643
    [No Abstract]   [Full Text] [Related]  

  • 23. [Metastasized renal cell carcinoma - research subjects needed!].
    Aktuelle Urol; 2014 Mar; 45(2):99. PubMed ID: 24700063
    [No Abstract]   [Full Text] [Related]  

  • 24. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis.
    Procopio G; Bellmunt J; Dutcher J; Bracarda S; Knox J; Brueckner A; Molnar I; Escudier B; Hutson TE
    Br J Cancer; 2013 Feb; 108(2):311-8. PubMed ID: 23322192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.
    Fairfax BP; Pratap S; Roberts IS; Collier J; Kaplan R; Meade AM; Ritchie AW; Eisen T; Macaulay VM; Protheroe A
    BMC Cancer; 2012 Dec; 12():590. PubMed ID: 23231599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.
    Vin H; Ching G; Ojeda SS; Adelmann CH; Chitsazzadeh V; Dwyer DW; Ma H; Ehrenreiter K; Baccarini M; Ruggieri R; Curry JL; Ciurea AM; Duvic M; Busaidy NL; Tannir NM; Tsai KY
    Mol Cancer Ther; 2014 Jan; 13(1):221-9. PubMed ID: 24170769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Education and imaging. Hepatology: Complete regression of locally advanced hepatocellular carcinoma following Sorafenib monotherapy.
    Kumar S
    J Gastroenterol Hepatol; 2015 Mar; 30(3):438. PubMed ID: 25707790
    [No Abstract]   [Full Text] [Related]  

  • 28. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
    Monk P; Lam E; Mortazavi A; Kendra K; Lesinski GB; Mace TA; Geyer S; Carson WE; Tahiri S; Bhinder A; Clinton SK; Olencki T
    J Immunother; 2014 Apr; 37(3):180-6. PubMed ID: 24598448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorafenib in renal cell carcinoma.
    Davoudi ET; bin-Noordin MI; Javar HA; Kadivar A; Sabeti B
    Pak J Pharm Sci; 2014 Jan; 27(1):203-8. PubMed ID: 24374450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib-induced tuberculosis reactivation.
    Teo M; O'Connor TM; O'Reilly SP; Power DG
    Onkologie; 2012; 35(9):514-6. PubMed ID: 23007150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of antiangiogenic therapy.
    von Falck C; Wacker F; Rosenthal H
    J Vasc Interv Radiol; 2012 Nov; 23(11):1503. PubMed ID: 23101922
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
    Szmit S; Zaborowska M; Waśko-Grabowska A; Żołnierek J; Nurzyński P; Filipiak KJ; Opolski G; Szczylik C
    Kidney Blood Press Res; 2012; 35(6):468-76. PubMed ID: 22688785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis.
    Karashima T; Fukuhara H; Tamura K; Ashida S; Kamada M; Inoue K; Taguchi T; Kuroda N; Shuin T
    Int J Urol; 2013 Sep; 20(9):923-30. PubMed ID: 23379954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The histologic spectrum of epithelial neoplasms induced by sorafenib.
    Kwon EJ; Kish LS; Jaworsky C
    J Am Acad Dermatol; 2009 Sep; 61(3):522-7. PubMed ID: 19700018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
    Dasanu CA; Alexandrescu DT; Dutcher J
    South Med J; 2007 Mar; 100(3):328-30. PubMed ID: 17396743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients.
    Yang X; Pan X; Cheng X; Kuang Y; Cheng Y
    Am J Ther; 2017; 24(1):e81-e101. PubMed ID: 26322676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypothyroidism during treatment with tyrosine kinase inhibitors.
    Zygulska AL; Krzemieniecki K; Sowa-Staszczak A
    Endokrynol Pol; 2012; 63(4):302-6. PubMed ID: 22933166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of preoperative sorafenib therapy in facilitating cytoreductive surgery in renal cell carcinoma.
    Bhatt VR; Ganti AK; Schwarz JK; Wang J
    Future Oncol; 2014 Apr; 10(5):703-6. PubMed ID: 24799051
    [No Abstract]   [Full Text] [Related]  

  • 39. Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
    Hainsworth JD; Waterhouse DM; Penley WC; Shipley DL; Thompson DS; Webb CD; Anthony Greco F
    Cancer Invest; 2013 Jun; 31(5):323-9. PubMed ID: 23614653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
    Callaghan C; Peralta D; Liu J; Mandava SH; Maddox M; Dash S; Tarr MA; Lee BR
    J Pharm Sci; 2016 Jan; 105(1):284-92. PubMed ID: 26852860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.